Concerns growing over Pfizer’s tactics to advance into generic market

Controversial tactics that Pfizer Korea is using to protect its revenue through selling of seven generic drugs could become a model for the domestic pharmaceutical industry as more multinational companies lose exclusive rights to distribute their most valuable medicines, according to industry officials.

“They will probably extract greater profits than they would have,” said a pharmaceutical ...